Concurrent Chemoradiotherapy with S-1 for T2N0 Glottic Squamous Cell Carcinoma

DOI PDF Web Site 被引用文献7件 参考文献36件
  • NONOSHITA Takeshi
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • SHIOYAMA Yoshiyuki
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • NAKAMURA Katsumasa
    Department of Radiology, Kyushu University Hospital at Beppu
  • NAKASHIMA Torahiko
    Department of Otorhinology, Graduate School of Medical Sciences, Kyushu University
  • OHGA Saiji
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • YOSHITAKE Tadamasa
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • OHNISHI Kayoko
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • TERASHIMA Kotaro
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • ASAI Kaori
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University
  • HONDA Hiroshi
    Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University

この論文をさがす

抄録

In this study, we evaluated the feasibility, efficacy and toxicity of concurrent chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium) for T2N0 glottic carcinoma. A total of 23 patients with T2N0 glottic carcinoma received chemoradiotherapy with S-1. Radiotherapy consisted of five daily fractions of 2 Gy per week, to a total median dose of 70 Gy. S-1 was administered 65 mg/m2 per day for 4 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and twice a day until the end of radiotherapy. Initial local control rate of the primary tumor was achieved in all patients. The median follow-up period for all patients was 38 months. The 3-year local control rate was 95.4%. Regarding adverse reactions, grade 3 mucositis upon clinical examination, mucositis upon functional/symptomatic examination, dysphagia, hepatic toxicity and anemia were observed in 13, 2, 2, 1 and 1 patients, respectively. This chemoradiotherapy did not result in grade 4 acute toxicity or severe late toxicity. Chemoradiotherapy with S-1 was feasible, well tolerated and effective. This therapy is suggested as a possible regimen for improving local control of T2N0 glottic carcinoma.

収録刊行物

被引用文献 (7)*注記

もっと見る

参考文献 (36)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ